AbbVie Inc. $ABBV Shares Purchased by Legal & General Group Plc

Key Points

• Legal & General Group Plc increased its AbbVie stake by 1.1% in the fourth quarter, holding 12.13 million shares worth about $2.77 billion. AbbVie now makes up 0.6% of the firm’s portfolio and is its 17th-largest holding.
• AbbVie’s latest earnings beat expectations, reporting $2.65 EPS versus the $2.59 consensus and $15 billion in revenue versus $14.72 billion expected. Revenue rose 12.4% year over year, and analysts now expect full-year EPS of 14.3.
• Analysts remain broadly bullish, with several firms raising price targets and the stock carrying a Moderate Buy consensus. New positive catalysts include EMA support for MAVIRET in acute hepatitis C, a positive CHMP opinion for Allergan Aesthetics’ Boey, and fresh oncology data highlighted at ASCO 2026.

Legal & General Group Plc raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,133,331 shares of the company's stock after acquiring an additional 129,247 shares during the period. AbbVie makes up 0.6% of Legal & General Group Plc's investment portfolio, making the stock its 17th biggest holding. Legal & General Group Plc owned 0.69% of AbbVie worth $2,772,345,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Wellington Management Group LLP raised its stake in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Vanguard Group Inc. grew its position in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after buying an additional 3,032,438 shares during the last quarter. Raymond James Financial Inc. increased its stake in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the period. Alliancebernstein L.P. increased its stake in AbbVie by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock valued at $1,685,918,000 after buying an additional 1,758,657 shares during the period. Finally, Amundi increased its stake in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

AbbVie Stock Performance

AbbVie stock opened at $216.02 on Monday. AbbVie Inc. has a one year low of $181.71 and a one year high of $244.81. The business has a fifty day moving average of $208.72 and a two-hundred day moving average of $219.73. The company has a market cap of $381.65 billion, a P/E ratio of 106.41, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie's quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.46 earnings per share. Sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Morgan Stanley raised their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a research note on Thursday, April 30th. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 17th. Piper Sandler raised their price objective on shares of AbbVie from $294.00 to $298.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price objective on the stock in a report on Thursday, April 30th. Finally, Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and an average price target of $253.43.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.